Oxidative stress, an imbalance between toxic compounds and defense mechanisms, and prevalent in the dialysis , has been to numerous undesirable complications in end-stage renal disease patients linked. The by the overproduction by the overproduction of reactive oxygen species , or toxic compounds, and lack of antioxidants to fight these toxins. In fact, the process of hemodialysis to a loss of the necessary these antioxidants.
References1) ‘The efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis. Results of a phase II randomized placebo-controlled multicenter trial ‘ Kappos et al, ECTRIMS 2010.Therefore I strongly recommend that the FTC, the question in future drug companies merger and make sure that investigate such mergers, so that this problem will not exacerbated. The FTC should also examine which. Of supply shortages, ensure that it is not create in any way by any of anti-competitive practices.